Redeye leaves an initial comment on the strong Q2 report, where OPEX cuts and higher distributor sal...
Uncertainty remains The uncertainties regarding tariffs have not diminished during the months foll...
Redeye provides a brief comment on FMG’s downward revision of its full-year guidance.
Redeye remains confident on the case but makes some further downward adjustments to our forecasts on...
Studentbostäder i Norden rapporterar ett andra kvartal i linje med våra förväntningar påverkat av sä...
Beijer Alma levererar en mycket stark kvartalsrapport som visar på både organisk och men främst förv...
Redeye is encouraged by FluoGuide announcing a non-exclusive collaboration with global medtech compa...
Omsättningen i Q2 uppgick till 19,8 MSEK, något över förväntan.
Order backlog at its highest level since Q2/23 Consti’s steady development continued during the se...
Fastighetsbolaget Trianon har levererat ett starkt andra kvartal med ökade hyresintäkter och en förb...
Redeye updates its estimates and fair value range following CTEK’s Q2 report, which was released las...
Redeye updates its estimates and valuation after Safeture’s Q2 2025 report.
Redeye comments on IRLAB’s announcement of the outcome of its rights issue, which raised gross proce...
Q2 figures pre-announced OrganoClick reported sales of SEK 30m (-23% y-o-y) and EBIT of -4.
Redeye updates its estimates and valuation following Tradedoubler’s Q2 2025 report.
Redeye updates its estimates and valuation following Lagercrantz’s Q1 2025/2026 report.
Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 8%, with the ...
Redeye comments on Camurus' Q2 report 2025, which was in line with our estimates on a constant curre...
Redeye provides an update following Truecaller’s Q2 2025 report, which came in somewhat softer than ...
Redeye updates on Invisio after Q2-results which saw solid topline but weaker-than-expected profitab...
